Three‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the rapamycin‐eluting stent evaluated at rotterdam cardiology hospital—(RESEARCH) registry

Authors:
  • NKNeville Kukreja
    Neville Kukreja

Abstract
Background: We previously reported that the 1‐year survival‐free from target lesion revascularization was 97.4% in patients with chronic total occlusion (CTO) treated with sirolimus‐eluting stents (SES). There are currently no long‐term results of the efficacy of SES in this subset of lesions. We assessed the 3‐year clinical outcomes of 147 patients with CTO treated with either SES or bare metal stents (BMS). Methods and Results: A total of 147 (BMS = 71, SES = 76) patients were included. Four patients died in the BMS group while five patients died in the SES group, P = 0.8; two myocardial infarctions occurred in both groups, P = 0.9; and target vessel revascularization was performed in nine patients in the BMS and seven in the SES group, P = 0.5. The cumulative event‐free survival of MACE was 81.7% in BMS group and 84.2% in SES group, P = 0.7. Two patients of the SES group had a coronary aneurism at 3‐year angiographic follow‐up. Conclusions: The use of SES was no longer associated with significantly lower rates of target vessel revascularization and major adverse cardiac events in patients with CTOs after 3 years of follow‐up compared with BMSs.

This publication has 14 references indexed in Scilit: